A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

Site Image

Study Overview

The purpose of this research study is to: 1) evaluate how well IMR-687 is tolerated in subjects with β-thalassemia and how safe it is, 2) measure the amount of IMR-687 in your blood and 3) evaluate what the drug does to the red blood cells and other blood markers associated with your disease.

Drug IMR-687 is not FDA approved for use.

This study will look at two different dose levels of IMR-687 and compare how these work to a placebo, which is a substance that looks like an active drug but has no active drug in it.

This study is a randomized trial which means that participants will be randomly assigned to one of the study drug doses (high dose or low dose of IMR-687, or placebo).

  • Study Identifier: 844255

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu